Compare Stocks → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AGENASDAQ:IFRXOTCMKTS:IGXTNASDAQ:ITRMNASDAQ:KZR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGEAgeX Therapeutics$2.58$11.07▼$35.71$11.96M1.189,164 shs3,753 shsIFRXInflaRx$1.54$1.60$1.14▼$7.25$68.84M1.29247,298 shs317,779 shsIGXTIntelGenx Technologies$0.18-5.4%$0.16$0.09▼$0.26$30.74M2.4290,580 shs46,392 shsITRMIterum Therapeutics$1.54-3.1%$1.54$0.62▼$2.50$21.36M2.35198,616 shs225,397 shsKZRKezar Life Sciences$0.90$0.91$0.67▼$3.37$65.74M0.48861,360 shs1.16 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGEAgeX Therapeutics0.00%-16.48%+4,457.35%+4,512.99%+2,675.00%IFRXInflaRx0.00%0.00%-6.67%-5.52%-13.48%IGXTIntelGenx Technologies-4.35%+8.17%+19.08%+27.44%-2.22%ITRMIterum Therapeutics-3.14%-2.53%+16.67%-21.83%+58.76%KZRKezar Life Sciences-0.16%-6.57%-7.00%-4.83%-72.09%This consistently signaled gains of 453%... 610%... and even 1036%... (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGEAgeX TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIFRXInflaRx2.7976 of 5 stars3.63.00.00.02.01.71.3IGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AITRMIterum Therapeutics1.3594 of 5 stars3.52.00.00.02.30.00.6KZRKezar Life Sciences4.2006 of 5 stars3.22.00.04.63.91.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGEAgeX TherapeuticsN/AN/AN/AN/AIFRXInflaRx3.25Buy$11.67657.58% UpsideIGXTIntelGenx TechnologiesN/AN/AN/AN/AITRMIterum Therapeutics3.00Buy$6.00289.61% UpsideKZRKezar Life Sciences2.33Hold$11.001,120.05% UpsideCurrent Analyst RatingsLatest IFRX, IGXT, KZR, ITRM, and AGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/15/2024KZRKezar Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.003/6/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.002/7/2024ITRMIterum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$6.001/25/2024IFRXInflaRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGEAgeX Therapeutics$140K0.00N/AN/A($16.07) per share0.00IFRXInflaRx$70K983.40N/AN/A$2.48 per share0.62IGXTIntelGenx Technologies$1.04M29.56N/AN/A($0.07) per share-2.51ITRMIterum TherapeuticsN/AN/AN/AN/A$2.29 per shareN/AKZRKezar Life Sciences$7M9.38N/AN/A$2.58 per share0.35Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGEAgeX Therapeutics-$14.80M-$13.030.00N/AN/A-10,424.65%N/A-120.90%3/29/2024 (Estimated)IFRXInflaRx-$46.18M-$0.86N/AN/AN/AN/A-40.10%-36.24%5/9/2024 (Estimated)IGXTIntelGenx Technologies-$9.93M-$0.06N/A∞N/A-955.44%N/A-128.18%N/AITRMIterum Therapeutics-$44.43M-$2.44N/AN/AN/AN/A-216.28%-57.67%N/AKZRKezar Life Sciences-$101.87M-$1.41N/AN/AN/AN/A-43.08%-37.59%5/9/2024 (Estimated)Latest IFRX, IGXT, KZR, ITRM, and AGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023IGXTIntelGenx TechnologiesN/A-$0.02-$0.02-$0.03N/A$0.43 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGEAgeX TherapeuticsN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/AIGXTIntelGenx TechnologiesN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGEAgeX TherapeuticsN/A0.130.36IFRXInflaRxN/A6.505.82IGXTIntelGenx TechnologiesN/A0.410.40ITRMIterum Therapeutics3.632.352.35KZRKezar Life Sciences0.0511.6611.66OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGEAgeX Therapeutics12.50%IFRXInflaRx42.39%IGXTIntelGenx TechnologiesN/AITRMIterum Therapeutics9.21%KZRKezar Life Sciences67.90%Insider OwnershipCompanyInsider OwnershipAGEAgeX Therapeutics6.50%IFRXInflaRx16.30%IGXTIntelGenx Technologies42.05%ITRMIterum Therapeutics5.40%KZRKezar Life Sciences7.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGEAgeX Therapeutics51.08 million1.01 millionNot OptionableIFRXInflaRx6244.70 million37.42 millionOptionableIGXTIntelGenx Technologies4174.66 million101.21 millionNot OptionableITRMIterum Therapeutics1413.44 million12.71 millionNot OptionableKZRKezar Life Sciences5872.80 million67.05 millionNot OptionableIFRX, IGXT, KZR, ITRM, and AGE HeadlinesSourceHeadlineHead to Head Analysis: Kezar Life Sciences (NASDAQ:KZR) & Humanigen (NASDAQ:HGEN)americanbankingnews.com - March 28 at 1:30 AMFrom Pennies to Fortunes: 3 Stocks Set to Make Millionairesinvestorplace.com - March 27 at 4:30 PMKezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Increase in Short Interestamericanbankingnews.com - March 20 at 3:20 AMKezar Life Sciences' (KZR) Buy Rating Reaffirmed at HC Wainwrightamericanbankingnews.com - March 19 at 2:52 AMHC Wainwright Reaffirms Buy Rating for Kezar Life Sciences (NASDAQ:KZR)marketbeat.com - March 18 at 6:43 PMKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 6.0% in Februarymarketbeat.com - March 18 at 11:22 AMDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026investorplace.com - March 16 at 6:56 AMKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023investorplace.com - March 14 at 10:03 PMKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updatebusinesswire.com - March 14 at 4:01 PMEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefeconfinanznachrichten.de - March 12 at 3:21 PMKezar Life Sciences, Inc. (KZR)finance.yahoo.com - March 3 at 2:56 PMAcadian Asset Management LLC Has $988,000 Position in Kezar Life Sciences, Inc. (NASDAQ:KZR)marketbeat.com - February 29 at 5:46 AMKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 28 at 5:39 PMEverest Medicines & Kezar Life Sciences receive China NMPA nod to begin phase 2b PALIZADE trial of zetomipzomib in patients with lupus nephritispharmabiz.com - February 28 at 2:37 AMBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Marketmarkets.businessinsider.com - February 27 at 4:36 PMEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritisbusinesswire.com - February 26 at 6:30 PMEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritisprnewswire.com - February 26 at 6:10 PM3 Top Penny Stocks for 5,000% Upside in 2024 and Beyondinvestorplace.com - February 25 at 2:12 PMKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and Datesbenzinga.com - February 22 at 12:59 AMKezar Life Sciences Inc.thestreet.com - February 19 at 7:24 PM3 Penny Stocks Poised for an Unbelievable 1,000% Jumpfinance.yahoo.com - February 10 at 9:24 AMKezar Life Sciences Inc KZRmorningstar.com - January 31 at 6:24 PMKZR Jan 2025 17.500 callfinance.yahoo.com - January 18 at 5:16 PMKezar Life Sciences: Results Of Operations And Financial Conditioncbonds.com - January 10 at 1:58 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAgeX TherapeuticsNYSE:AGEAgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.InflaRxNASDAQ:IFRXInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.IntelGenx TechnologiesOTCMKTS:IGXTIntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.Iterum TherapeuticsNASDAQ:ITRMIterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.Kezar Life SciencesNASDAQ:KZRKezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.